Joseph Henderson, MD
Urogynecology and Reconstructive Pelvic Surgery · Richmond Heights, OHNPI 1528200904
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,571 of the $5,958 with a category attached, or 76.7%. It is spread thinly across 19 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $2,169, 2.3 times the $934 reported in 2019.
Across 96 payments — averaging $62.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bluewind Medical$1K
- Medtronic$1K
- Caldera Medical, Inc$687
- Boston Scientific$640
- Axonics, Inc.$551
- Astellas Pharma US Inc$452
- plus $1K from 13 others
What the payments were for
- Travel & lodging$1,30222%
- Food & beverage$4,57177%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bluewind Medical | 5 | $1,324 |
| Medtronic(2 entities) | 15 | $1,094 |
| Caldera Medical, Inc | 8 | $687 |
| Boston Scientific | 8 | $640 |
| Axonics, Inc. | 9 | $551 |
| Astellas Pharma US Inc | 19 | $452 |
| Coloplast | 3 | $312 |
| Sumitomo Pharma America, Inc. | 5 | $212 |
| AbbVie(2 entities) | 8 | $191 |
| Urovant Sciences Inc | 2 | $110 |
| Coopersurgical, Inc. | 2 | $109 |
| Applied Medical Resources Corporation | 1 | $77 |
| Dentsply IH AB | 3 | $67 |
| Therapeuticsmd, Inc. | 3 | $46 |
| Rochester Medical Corporation | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Convatec Inc. | 1 | $14 |
| Dentsply IH Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REVI$1,168
- INTERSTIM$525
- Desara$392
- Bulkamid$358
- Vertessa$277
- Axonics$223
- GEMTESA$136
- ALTIS$133
- Advantage System$132
- GENERAL PELVIC ORGAN PROLAPSE$130
- Axonics r-SNM System$122
- MYRBETRIQ$117
- ADVANTAGE FIT$102
How this compares
$5,958 in reported general payments places this provider in the 65th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 616 | $421,157 |
| GemtesaVibegron | 339 | $258,964 |
| Estradiol | 752 | $52,333 |
| Mirabegron ErMirabegron | 47 | $23,054 |
| Methenamine Hippurate | 177 | $10,890 |
| Oxybutynin Chloride ErOxybutynin Chloride | 338 | $9,300 |
| Trimethoprim | 195 | $7,702 |
| Solifenacin Succinate | 50 | $6,023 |
| YuvafemEstradiol | 28 | $5,576 |
| NitrofurantoinNitrofurantoin Macrocrystal | 138 | $5,568 |
| Fosfomycin Tromethamine | 20 | $5,111 |
| Tolterodine Tartrate ErTolterodine Tartrate | 41 | $4,699 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 259 | $3,835 |
| Cefdinir | 71 | $2,748 |
| Trospium Chloride | 32 | $2,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $452 | $421,157616 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $212 | $258,964339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Richmond Heights
- Costas ApostolisStrongsville$982K
- Mickey KarramWest Chester$127K
- Sangeeta MahajanMayfield Hts$48K
- Emily SlopnickCleveland$37K
- Mitesh ParekhZanesville$33K
- Andrew CroakMaumee$26K
- Ly Hoang RobertsCleveland$23K
- Marie ParaisoCleveland$20K
- Omer AnisCleveland$17K
- Nadine KassisToledo$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.